Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS VIVUS Inc. daily Stock Chart
VVUS [NASD]
VIVUS Inc.
Index- P/E- EPS (ttm)-1.02 Insider Own0.60% Shs Outstand104.00M Perf Week13.51%
Market Cap131.04M Forward P/E- EPS next Y-0.26 Insider Trans-3.85% Shs Float97.36M Perf Month-3.08%
Income-106.10M PEG- EPS next Q-0.17 Inst Own66.90% Short Float35.91% Perf Quarter-51.54%
Sales110.80M P/S1.18 EPS this Y53.80% Inst Trans0.99% Short Ratio25.98 Perf Half Y-54.84%
Book/sh0.20 P/B6.30 EPS next Y72.30% ROA-29.80% Target Price3.15 Perf Year-69.42%
Cash/sh2.64 P/C0.48 EPS next 5Y0.80% ROE-152.70% 52W Range0.94 - 4.82 Perf YTD-56.25%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-16.10% 52W High-73.86% Beta2.03
Dividend %- Quick Ratio4.60 Sales past 5Y29.50% Gross Margin67.00% 52W Low34.09% ATR0.11
Employees94 Current Ratio4.70 Sales Q/Q5.00% Oper. Margin-35.80% RSI (14)47.20 Volatility7.60% 8.13%
OptionableYes Debt/Eq11.22 EPS Q/Q-92.00% Profit Margin-95.80% Rel Volume1.35 Prev Close1.24
ShortableYes LT Debt/Eq10.52 EarningsAug 04 AMC Payout- Avg Volume1.35M Price1.26
Recom2.80 SMA2011.38% SMA50-25.01% SMA200-48.80% Volume1,822,333 Change1.61%
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Oct-29-10Reiterated JMP Securities Mkt Outperform $12 → $16
Aug-03-10Downgrade Brean Murray Hold → Sell $2
Sep-03-15 12:08PM  5 Stocks Under $10 Set to Soar at TheStreet
Sep-01-15 02:49PM  4 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Aug-31-15 08:40AM  Why VIVUS (VVUS) Could Shock the Market Soon
Aug-23-15 10:57AM  The 3 Most Disappointing Drug Launches of All Time at Motley Fool
Aug-18-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Aug-14-15 05:04PM  Stocks Trading Near Their 52-Week Lows: 4 Hot Picks
Aug-13-15 09:18AM  VIVUS Inc. (VVUS) in Focus: Stock Jumps 5.4%
07:30AM  VIVUS (VVUS) Is in Oversold Territory: What's Next?
Aug-06-15 01:04PM  VIVUS INC Financials -10.00%
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron, Baxalta and VIVUS - Press Releases
06:04AM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Aug-05-15 08:09PM  10-Q for VIVUS, Inc. at Company Spotlight
04:49PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
10:44AM  Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog
Aug-04-15 01:00PM  Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog -9.72%
Aug-03-15 06:16AM  VIVUS INC Files SEC form 10-Q, Quarterly Report
Jul-31-15 05:55PM  Bay Area obesity drug maker slims down as market slows at bizjournals.com -12.72%
04:24PM  Express Scripts excludes 20 more drugs from 2016 coverage
03:52PM  Edited Transcript of VVUS earnings conference call or presentation 30-Jul-15 8:30pm GMT
03:25PM  Vivus (VVUS) Stock Falls Following Earnings Release, Restructuring Plan at TheStreet
11:06AM  VIVUS (VVUS) Q2 Loss Narrower, Restructuring Announced - Analyst Blog
Jul-30-15 05:02PM  Vivus reports 2Q loss
04:30PM  VIVUS Inc Earnings Call scheduled for 4:30 pm ET today
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  VIVUS Reports Second Quarter 2015 Financial Results Marketwired
Jul-23-15 07:00AM  VIVUS Announces Date of Second Quarter 2015 Update and Financial Results Conference Call GlobeNewswire -5.94%
Jul-21-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Jul-05-15 02:18PM  Obesity Statistics Take a Wrong Turn in This Latest Study at Motley Fool
Jun-24-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
May-29-15 11:22AM  Vivus gets a vote of confidence
May-27-15 02:30PM  Zogenix says former obesity drug reduced seizures in study
May-14-15 07:00AM  VIVUS Announces Scientific Presentations Marketwired
May-08-15 08:09PM  10-Q for VIVUS, Inc. at Company Spotlight
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
May-06-15 04:19PM  VIVUS INC Files SEC form 10-Q, Quarterly Report
10:59AM  VIVUS Q1 Loss Narrower-than-Expected, Revenues Beat - Analyst Blog
May-05-15 06:34PM  VIVUS Reports First Quarter 2015 Financial Results at noodls
04:45PM  Vivus reports 1Q loss
04:30PM  VIVUS Inc Earnings Call scheduled for 4:30 pm ET today
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  VIVUS Reports First Quarter 2015 Financial Results Marketwired
07:07AM  Q1 2015 VIVUS Inc Earnings Release - After Market Close
Apr-30-15 07:22AM  VIVUS Announces Date of First Quarter 2015 Update and Financial Results Conference Call at noodls
07:00AM  VIVUS Announces Date of First Quarter 2015 Update and Financial Results Conference Call GlobeNewswire
Apr-28-15 04:04PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
07:00AM  VIVUS Announces New Discount Program Through Sam's Club for Qsymia Patients Marketwired
Apr-21-15 05:00PM  VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia at noodls
04:37PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:30PM  VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia Marketwired
Apr-17-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Apr-16-15 06:16PM  VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog
06:03AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-15-15 08:19PM  VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents at noodls
07:30PM  VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents Marketwired
Apr-14-15 07:06AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Apr-10-15 08:40AM  PharmalotPharmalittleGood Morning: We're Catching up on Eisai, HepC Research, Pfizer and Ebola at The Wall Street Journal
07:11AM  VIVUS to Present at Upcoming Investor Conference at noodls
07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
02:00AM  Eisai Drops On US Job Cuts, Still A Stunning Run On Alzheimer's Drug With Biogen at Barrons.com
Apr-09-15 06:24PM  Japanese Drug Company Eisai to Cut 25% of U.S. Jobs at The Wall Street Journal
Apr-02-15 02:40PM  Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? at The Wall Street Journal
Mar-30-15 04:31PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:19PM  VIVUS Announces Operational Update at noodls
04:05PM  VIVUS Announces Operational Update Marketwired
Mar-27-15 10:06PM  A Look at Pharma Company Dermira's Performance
08:25AM  Ahead of the Bell: Orexigen shares rise
06:50AM  The young & the restless: 6 who are hot at CNBC
Mar-20-15 05:29PM  Ferrellgas, Prothena Lead Friday's After-Hours Movers
Mar-10-15 01:51PM  4 Stocks Under $10 Making Big Moves Higher at TheStreet
07:06AM  VIVUS INC Files SEC form 8-K, Other Events
Mar-09-15 07:58AM  Early movers: GM, RTI, AMZN, AAPL, BBRY & more at CNBC
07:06AM  VIVUS INC Files SEC form 8-K, Other Events
Mar-06-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-03-15 03:36PM  Nasdaq backs off from 5,000
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
Feb-27-15 07:08PM  10-K for VIVUS, Inc. at Company Spotlight
Feb-26-15 11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog +5.91%
Feb-25-15 04:13PM  VIVUS INC Files SEC form 10-K, Annual Report EDGAR Online -8.96%
12:41PM  JPM Securities Picks Through Biotech News For Winners
09:40AM  VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog
Feb-24-15 05:12PM  Vivus reports 4Q loss AP
04:30PM  VIVUS Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q4 2014 Vivus Inc Earnings Release - After Market Close CCBN
Feb-20-15 03:47PM  Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus at TheStreet +7.46%
11:24AM  Activists want 'imminent retirement' of Ariad CEO at CNBC
07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
Feb-19-15 07:00AM  VIVUS Announces Date of Fourth Quarter and Year End 2014 Update and Financial Results Conference Call GlobeNewswire
Jan-29-15 07:09AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity Marketwired
Jan-27-15 04:06PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-26-15 04:06PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-23-15 06:25AM  Coverage initiated on Vivus by RBC Capital Mkts Briefing.com +6.20%
Jan-22-15 04:04PM  The 52-Week Low Club for Thursday at 24/7 Wall St. -5.15%
04:00PM  Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Zacks
Jan-15-15 07:01AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -7.33%
Jan-14-15 05:25PM  Obesity Device That Makes You Feel Full to Cost $15,000 at Bloomberg
01:55PM  5 Obesity Stocks Investors Are Watching Benzinga
Jan-13-15 04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online -6.36%
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Varghese Santosh TVP, Medical & Reg AffairsJul 01Sale2.327,89918,32641,234Jul 06 05:54 PM
Slebir John LSVP, Business Development & GCJul 01Sale2.329,21521,37963,584Jul 06 05:51 PM
Day WesleyVP, Clinical DevelopmentJul 01Sale2.327,88118,28449,118Jul 06 05:48 PM
Day WesleyVP, Clinical DevelopmentJan 29Sale2.784721,31256,999Jan 30 04:15 PM
Sanford Svai SCFO & Chief Accounting OfficerJan 29Sale2.784721,31265,559Jan 30 04:14 PM
MARSH GUY PVP, US Operations & GMJan 29Sale2.7823866231,487Jan 30 04:14 PM
Slebir John LSVP, Business Development & GCJan 29Sale2.786301,75172,799Jan 30 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 08Buy3.22217,900701,64012,500,000Jan 09 04:37 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 07Buy3.05282,100859,70112,282,100Jan 09 04:37 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 06Buy3.03147,936448,79812,000,000Jan 07 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 05Buy3.05328,8641,002,37111,852,064Jan 07 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 02Buy2.99218,400652,84511,523,200Jan 05 04:21 PM
NORTH TIDE CAPITAL, LLC10% OwnerDec 31Buy2.83304,800862,68011,304,800Jan 05 04:21 PM